CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Popular drugs like Ozemic and Monjauro aid in managing diabetes by lowering blood sugar levels. They have surged in ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

According to Sarah Marjoram, MS, RDN, a dietitian who specializes in food as medicine, “When it comes to improving health, ...